COST-EFFECTIVENESS REVIEWS BY HTA AGENCIES: A COMPARISON OF FACTORS LEADING TO UNFAVOURABLE REVIEWS FOR ONCOLOGY AGENTS

被引：0
|
作者：
Smith, N. [1 ]
Beckerman, R. [1 ]
机构：
[1] CBPartners, New York, NY USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HT4
引用
收藏
页码：A7 / A7
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews
    Diaby, Vakaramoko
    Almutairi, Reem D.
    Babcock, Aram
    Moussa, Richard K.
    Ali, Askal
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 353 - 364
  • [42] COMPARISON OF US ICER'S COST-EFFECTIVENESS THRESHOLD PRICE WITH COST PAID BY US PAYERS AND PUBLIC PAYERS IN OTHER HTA COUNTRIES
    El Moustaid, F.
    Elsea, D.
    Gosain, S.
    Meng, Y.
    VALUE IN HEALTH, 2020, 23 : S296 - S297
  • [43] Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies
    Greenhalgh, J
    Knight, C
    Hind, D
    Beverley, C
    Walters, S
    HEALTH TECHNOLOGY ASSESSMENT, 2005, 9 (09) : 1 - +
  • [44] COMPARISON OF FACTORS INFLUENCING RECENT REIMBURSEMENT DECISIONS OF ADVANCED NON-SMALL-CELL LUNG CANCER THERAPIES ACROSS LEADING HTA AGENCIES
    Kumar, P.
    Jyothsna, B. S.
    Outteridge, G.
    VALUE IN HEALTH, 2017, 20 (05) : A135 - A135
  • [45] Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews
    Gillian Eaglestone
    Evdoxia Gkaintatzi
    Harmony Jiang
    Charlotte Stoner
    Rosana Pacella
    Paul McCrone
    PharmacoEconomics - Open, 2023, 7 : 887 - 914
  • [46] The use of antibiotic pharmacodynamic end points in incremental cost-effectiveness analyses - A novel approach for consideration during hospital formulary reviews
    DeRyke, C. Andrew
    Kuti, Joseph L.
    Nicolau, David R.
    FORMULARY, 2007, 42 (04) : 252 - +
  • [47] Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews
    Eaglestone, Gillian
    Gkaintatzi, Evdoxia
    Jiang, Harmony
    Stoner, Charlotte
    Pacella, Rosana
    McCrone, Paul
    PHARMACOECONOMICS-OPEN, 2023, 7 (06) : 887 - 914
  • [48] ESTIMATING TRANSITION PROBABILITIES FROM PUBLISHED ONCOLOGY SURVIVAL DATA: COMPARISON OF METHODS AND IMPACT ON COST-EFFECTIVENESS
    Cupples, G.
    Krebs, E.
    Regier, D.
    VALUE IN HEALTH, 2024, 27 (12) : S619 - S619
  • [49] Is the Comparator in Your Diagnostic Cost-Effectiveness Model "Standard of Care"? Recommendations from Literature Reviews and Expert Interviews on How to Identify and Operationalize It
    Graziadio, Sara
    Gregg, Emily
    Allen, A. Joy
    Neveux, Paul
    Monz, Brigitta U.
    Davenport, Clare
    Mealing, Stuart
    Holmes, Hayden
    di Ruffano, Lavinia Ferrante
    VALUE IN HEALTH, 2024, 27 (05) : 585 - 597
  • [50] Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
    Qureshi, Nadeem
    Woods, Bethan
    Faria, Rita Neves de
    Goncalves, Pedro Saramago
    Cox, Edward
    Bee, Jo Leonardi
    Condon, Laura
    Weng, Stephen
    Akyea, Ralph K.
    Iyen, Barbara
    Roderick, Paul
    Humphries, Steve E.
    Rowlands, William
    Watson, Melanie
    Haralambos, Kate
    Kenny, Ryan
    Datta, Dev
    Miedzybrodzka, Zosia
    Byrne, Christopher
    Kai, Joe
    HEALTH TECHNOLOGY ASSESSMENT, 2023, 27 (16)
12345